The evolving strategies for the management of patients with metastatic gastric cancer: A narrative review and expert opinion

The evolving strategies for the management of patients with metastatic gastric cancer: A narrative review and expert opinion

Gastric cancer (GC) is recognized as one of the most common deadly malignancies worldwide and about 40–50% of patients present at diagnosis with an unresectable disease due to a locally advanced or already metastatic condition. Recently, therapeutic options for management of metastatic GC (mGC) have...

Full description

Bibliographic Details
Main Authors:	Stefano Cascinu, Maria Di Bartolomeo, Sara Lonardi, Giordano Beretta, Lorenzo Fornaro, Ferdinando De Vita
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Medicine
Subjects:	metastatic gastric cancer immune checkpoint inhibitors trifluridine/tipiracil management malnutrition tumor markers
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2022.1002435/full

Similar Items

TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without bevacizumab in previously treated patients with esophago-gastric adenocarcinoma, a randomised phase III trialResearch in context
by: Lene Baeksgaard Jensen, et al.
Published: (2024-04-01)

Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil
by: Mateusz Malik, et al.
Published: (2021-10-01)

A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer
by: Jiayun Zou, et al.
Published: (2023-12-01)

Brazilian cohort results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer
by: Celso Abdon Lopes de Mello, et al.
Published: (2022-12-01)

Сonfirmatory study of the efficacy and tolerability of trifluridine/tipiracil (TAS-102) therapy in the Russian population with chemorefractory metastatic colorectal cancer
by: M. Yu. Fedyanin, et al.
Published: (2020-12-01)

Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)
by: Naoki Takahashi, et al.
Published: (2023-08-01)

Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients
by: Matthias Unseld, et al.
Published: (2020-06-01)

Trifluridine/tipiracil as a therapeutic option in real life setting of metastatic colorectal cancer: An efficacy and safety analysis
by: Daniel Sur, et al.
Published: (2022-10-01)

Case report: Long-term survival in a patient with metastatic colorectal cancer treated with trifluridine/tipiracil in the third-line setting
by: Mohamed ELBassiouny
Published: (2023-03-01)

Clinical Effect of the C-Reactive Protein to Serum Albumin Ratio in Patients with Metastatic Gastric or Gastroesophageal Junction Cancer Treated with Trifluridine/Tipiracil
by: Itaru Hashimoto, et al.
Published: (2023-05-01)

Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study
by: Carlo Signorelli, et al.
Published: (2023-06-01)

External Validation of the Colon Life Nomogram for Predicting 12-Week Mortality in Dutch Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil in Daily Practice
by: Patricia A. H. Hamers, et al.
Published: (2022-10-01)

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
by: Florian Huemer, et al.
Published: (2020-09-01)

Long Term Real-World Outcomes of Trifluridine/Tipiracil in Metastatic Colorectal Cancer—A Single UK Centre Experience
by: Daniel Tong, et al.
Published: (2021-06-01)

Trifluridine / tipiracil (FTd / TPI, TAS-102) in the treatment of patients with metastatic colon cancer: from preclinical experiments to routine clinical practice
by: M. Yu. Fedyanin
Published: (2020-12-01)

Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study
by: Pilar García-Alfonso, et al.
Published: (2021-09-01)

Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma
by: Celia Lara-Morga, et al.
Published: (2023-04-01)

Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases
by: Nicholas Fidelman, et al.
Published: (2022-12-01)

Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis
by: Carlo Signorelli, et al.
Published: (2023-12-01)

The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program Results of a Survey on Daily Practice Patterns for Patients with Metastatic Colorectal Cancer—A Swiss Perspective in the Context of an International Viewpoint
by: Alexander R. Siebenhüner, et al.
Published: (2022-08-01)

Applicable Pharmacokinetic Study: Development and Validation of Bioanalytical LC-MS/MS Method for Simultaneous Determination of Tipiracil, Trifluridine and Its Two Metabolites 5-Trifluoromethyluracil, 5-Carboxy 2′-Deoxyuridine in Rat Plasma
by: Manal El-Gendy, et al.
Published: (2023-12-01)

Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, FTD/TPI, with Ramucirumab Murine Version DC101 in a Mouse Syngeneic Cancer Transplantation Model
by: Kenta Tsunekuni, et al.
Published: (2020-12-01)

Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)
by: Linde Kehmann, et al.
Published: (2023-05-01)

The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC
by: Gerald Prager, et al.
Published: (2021-06-01)

Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias
by: Daichi Watanabe, et al.
Published: (2023-11-01)

Metastatic gastric adenocarcinoma with appendiceal phlegmon: a case report
by: Farshid Mohammadi, et al.
Published: (2023-02-01)

High Frequency of Microsatellite Instability among Non-Metastatic Gastric Cancer
by: Khadijeh Fanaei, et al.
Published: (2022-10-01)

Third- and Late Line Treatments of Metastatic Gastric Cancer: Still More to Be Done
by: Marzia Mare, et al.
Published: (2022-09-01)

Survival predictors for second-line chemotherapy in Caucasian patients with metastatic gastric cancer
by: P Bohanes, et al.
Published: (2011-08-01)

Evolving Treatment Options for Metastatic Renal Cell Carcinoma (mRCC)
by: Eun-mi Yu, et al.
Published: (2023-04-01)

Subsite‐specific metastatic organotropism and risk in gastric cancer: A population‐based cohort study of the US SEER database and a Chinese single‐institutional registry
by: Ling Wang, et al.
Published: (2023-10-01)

The effect of the modified Glasgow prognostic score in metastatic gastric cancer
by: Ahmet Ozveren, et al.
Published: (2023-07-01)

The Effect Of Chemotherapy On Malnutrition In Geriatric Group With Metastatic Colorectal Cancer
by: Esat Namal
Published: (2019-01-01)

Construction of a nomogram to predict the survival of metastatic gastric cancer patients that received immunotherapy
by: Miaomiao Gou, et al.
Published: (2022-09-01)

Outcomes of Conversion Surgery for Metastatic Gastric Cancer Compared with In-Front Surgery Plus Palliative Chemotherapy or In-Front Surgery Alone
by: Ruo-Yi Huang, et al.
Published: (2022-04-01)

Prognostic value of tumor-infiltrating CD163+macrophage in patients with metastatic gastric cancer undergoing multidisciplinary treatment
by: Jun Kinoshita, et al.
Published: (2022-06-01)

The clustering status of detached gastric cancer cells inhibits anoikis-induced ferroptosis to promote metastatic colonization
by: Juan Sun, et al.
Published: (2024-02-01)

Real-world evidence of treatment patterns and survival of metastatic gastric cancer patients in Germany
by: Jaime Luna, et al.
Published: (2024-04-01)

Metastatic lymph node ratio to evaluate prognosis of patients with stage Ⅱ-Ⅲ gastric cancer after radical gastrectomy
by: DAI Zhiqiang, ZHENG Jinxin, TANG Zhaoqing, ZHANG Qi, GU Yuan, SHI Zhongyi, HU Guohua, SUN Yihong
Published: (2022-09-01)

Outcomes in patients with metastatic gastric cancer: a surveillance, epidemiology, and end results program (SEER) database analysis
by: Wenhan Li, et al.
Published: (2023-12-01)